206 related articles for article (PubMed ID: 37586766)
1. Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma.
Kaya NA; Tai D; Lim X; Lim JQ; Lau MC; Goh D; Phua CZJ; Wee FYT; Joseph CR; Lim JCT; Neo ZW; Ye J; Cheung L; Lee J; Loke KSH; Gogna A; Yao F; Lee MY; Shuen TWH; Toh HC; Hilmer A; Chan YS; Lim TK; Tam WL; Choo SP; Yeong J; Zhai W
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586766
[TBL] [Abstract][Full Text] [Related]
2. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.
Tai D; Loke K; Gogna A; Kaya NA; Tan SH; Hennedige T; Ng D; Irani F; Lee J; Lim JQ; Too CW; Ng MCH; Tham CK; Lam J; Koo SL; Chong HS; Goh GB; Huang HL; Venkatanarasimha N; Lo R; Chow PKH; Goh BKP; Chung A; Toh HC; Thng CH; Lim TKH; Yeong J; Zhai W; Chan CY; Choo SP
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1025-1035. PubMed ID: 34695377
[TBL] [Abstract][Full Text] [Related]
3. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.
Zhang S; Yuan L; Danilova L; Mo G; Zhu Q; Deshpande A; Bell ATF; Elisseeff J; Popel AS; Anders RA; Jaffee EM; Yarchoan M; Fertig EJ; Kagohara LT
Genome Med; 2023 Sep; 15(1):72. PubMed ID: 37723590
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
5. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
Yau T; Hsu C; Kim TY; Choo SP; Kang YK; Hou MM; Numata K; Yeo W; Chopra A; Ikeda M; Kuromatsu R; Moriguchi M; Chao Y; Zhao H; Anderson J; Cruz CD; Kudo M
J Hepatol; 2019 Sep; 71(3):543-552. PubMed ID: 31176752
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
[TBL] [Abstract][Full Text] [Related]
8. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.
Kokabi N; Arndt-Webster L; Chen B; Brandon D; Sethi I; Davarpanahfakhr A; Galt J; Elsayed M; Bercu Z; Cristescu M; Kappadath SC; Schuster DM
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1743-1752. PubMed ID: 36650357
[TBL] [Abstract][Full Text] [Related]
9. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
[TBL] [Abstract][Full Text] [Related]
10. Integrated use of
Filippi L; Evangelista L; Schillaci O
Expert Rev Gastroenterol Hepatol; 2023; 17(6):531-538. PubMed ID: 37194803
[TBL] [Abstract][Full Text] [Related]
11. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.
Wehrenberg-Klee E; Goyal L; Dugan M; Zhu AX; Ganguli S
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1799-1802. PubMed ID: 29845347
[TBL] [Abstract][Full Text] [Related]
12. Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma.
Hung YP; Shao YY; Lee JM; Hsu C; Hsu CH; Yang MH; Chao Y
J Chin Med Assoc; 2021 Feb; 84(2):144-150. PubMed ID: 33433132
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
16. The MAAPE score in intermediate and advanced hepatocellular carcinoma treated with Yttrium-90 resin microsphere radioembolization.
Wallace MC; Samuelson S; Khoo T; Ooi J; Tibballs J; Ferguson J; Preen DB; Knuiman M; Garas G; MacQuillan G; Adams LA; Jeffrey GP
J Gastroenterol Hepatol; 2020 Nov; 35(11):1945-1952. PubMed ID: 32036614
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
Kambhampati S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
[TBL] [Abstract][Full Text] [Related]
18. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab for the treatment of hepatocellular carcinoma.
Chiew Woon L; Joycelyn Jie Xin L; Su Pin C
Expert Opin Biol Ther; 2020 Jul; 20(7):687-693. PubMed ID: 32249635
[TBL] [Abstract][Full Text] [Related]
20. Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab.
Adcock CS; Puneky LV; Campbell GS
Cureus; 2019 Feb; 11(2):e4083. PubMed ID: 31019861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
